A
Aspect Biosystems
Biotech & Life Sciences · Vancouver, Canada · Founded 2013
Commercializing cutting-edge bioprinting technologies MoreLess
Aspect Biosystems is a pioneering company in the field of regenerative medicine, specializing in the development of bioprinted tissue therapeutics. The company operates in the biotechnology and pharmaceutical markets, serving clients that include leading pharmaceutical and biotechnology firms. Aspect Biosystems utilizes a transformative platform technology that combines proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design to create allogeneic tissue therapeutics. This innovative approach aims to address some of the most significant challenges in regenerative medicine by developing a targeted pipeline of bioprinted tissue therapeutics.
Aspect Biosystems' business model focuses on strategic collaborations and partnerships with top-tier pharmaceutical and biotechnology companies. The company generates revenue through these collaborations, as well as through securing significant funding from investors. Under the leadership of co-founder and CEO Tamer Mohamed, Aspect Biosystems has built a world-class team and secured substantial financial backing to advance its mission.
The company is headquartered in Vancouver, BC, Canada, and offers a range of employee benefits, including competitive salaries, stock options, fully paid extended healthcare, life insurance, and professional development opportunities.
Keywords: bioprinting, tissue therapeutics, regenerative medicine, biotechnology, pharmaceutical, platform technology, therapeutic cells, biomaterials, computational design, strategic collaborations.
Company overview
Aspect Biosystems company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2013
- Headquarters
- Vancouver, Canada
- Employees
- 145
- Open positions
- 8
- Dealroom signal
- 90.3
Valuation & funding
Aspect Biosystems funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PROJECT, REAL ESTATE, INFRASTRUCTURE FINANCEOther financing | Apr 2026 | $58M | — | Innovation, Science and Economic Development Canada | ↗ |
| SERIES BOther financing | Jan 2025 | $115M | $460M | Novo Nordisk · Pallasite Ventures · Radical Ventures · Pangaea Ventures | ↗ |
| GRANTOther financing | Jul 2024 | $73M | — | Government of Canada · Government of British Columbia | ↗ |
| GRANTOther financing | Mar 2023 | $3.6M | — | Undisclosed | ↗ |
| FundingOther financing | May 2022 | $0 | — | Page One Ventures | ↗ |
| GRANTOther financing | Jan 2022 | PacifiCan | — | ||
| SERIES AOther financing | Jun 2020 | Pallasite Ventures · Pangaea Ventures · Hedgewood · Radical Ventures | — | ||
| SERIES AOther financing | Jan 2020 | Radical Ventures · Pallasite Ventures | ↗ | ||
| GRANTOther financing | Nov 2018 | Undisclosed | — | ||
| EARLY VCOther financing | May 2018 | Genome British Columbia | — |
Growth signals
Aspect Biosystems website traffic
Latest recorded traffic for Aspect Biosystems is 14K monthly website visits, down 22.2% over the last three months. Aspect Biosystems's team grew 18.9% over the past year.
Hiring
Open positions at Aspect Biosystems
Current openings linked to this company in Dealroom.
Comparisons
Aspect Biosystems compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Aspect Biosystems's talent
Source: Dealroom Talent Intelligence.
Investors
26 investors on Aspect Biosystems's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Aspect Biosystems has talent and traffic
team presence
In the news
Latest news about Aspect Biosystems
Recent press, funding announcements, and product moves mentioning Aspect Biosystems — open to read from the original sources.
Market sentiment
What the market is saying about Aspect Biosystems
An AI-synthesized read of the highest-engagement posts about Aspect Biosystems on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aspect Biosystems’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.